Research & Literature

Patient-reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments.

Gavin AT, Drummond FJ, Donnelly C, et al.

BJU international 2015; (116(3)):397-406 doi:10.1111/bju.13036.

Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement.

Resnick MJ, Lacchetti C, Bergman J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(9)):1078-85 doi:10.1200/JCO.2014.60.2557.

Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance.

Parker PA, Davis JW, Latini DM, et al.

BJU international 2016; (117(3)):469-77 doi:10.1111/bju.13099.

Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

Body JJ, Bone HG, de Boer RH, et al.

European journal of cancer (Oxford, England : 1990) 2015; (51(13)):1812-21.

Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.

Gartrell BA, Coleman R, Efstathiou E, et al.

European urology 2015; (68(5)):850-8.

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Epstein JI, Zelefsky MJ, Sjoberg DD, et al.

European urology 2016; (69(3)):428-35.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016; (24(1)):447-455 doi:10.1007/s00520-015-2904-5.

The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Epstein JI, Egevad L, Amin MB, et al.

The American journal of surgical pathology 2016; (40(2)):244-52 doi:10.1097/PAS.0000000000000530.

Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials.

Teleni L, Chan RJ, Chan A, et al.

Endocrine-related cancer 2016; (23(2)):101-12 doi:10.1530/ERC-15-0456.

Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.

Shen X, Kumar P

The Journal of urology 2016; (195(5)):1397-1402 doi:10.1016/j.juro.2015.11.056.

Erectile dysfunction after radical prostatectomy: prevalence, medical treatments, and psychosocial interventions.

Emanu JC, Avildsen IK, Nelson CJ

Current opinion in supportive and palliative care 2016; (10(1)):102-7 doi:10.1097/SPC.0000000000000195.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Scher HI, Morris MJ, Stadler WM, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(12)):1402-18 doi:10.1200/JCO.2015.64.2702.

Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Kweldam CF, Kümmerlin IP, Nieboer D, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(6)):630-6 doi:10.1038/modpathol.2016.49.

International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading.

Egevad L, Delahunt B, Srigley JR, Samaratunga H

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2016; (124(6)):433-5 doi:10.1111/apm.12533.

Primary Care of the Prostate Cancer Survivor.

Noonan EM, Farrell TW

American family physician 2016; (93(9)):764-70.

Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure.

Katz A, Formenti SC, Kang J

Frontiers in oncology 2016; (6()):168 doi:10.3389/fonc.2016.00168.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, et al.

European urology 2017; (71(4)):630-642 doi:10.1016/j.eururo.2016.08.002.

Familial prostate cancer.

Giri VN, Beebe-Dimmer JL

Seminars in oncology 2016; (43(5)):560-565 doi:10.1053/j.seminoncol.2016.08.001.

Redefining and Contextualizing the Hospital Volume-Outcome Relationship for Robot-Assisted Radical Prostatectomy: Implications for Centralization of Care.

Gershman B, Meier SK, Jeffery MM, et al.

The Journal of urology 2017; (198(1)):92-99 doi:10.1016/j.juro.2017.01.067.

Brachytherapy boost for prostate cancer: Trends in care and survival outcomes.

Glaser SM, Dohopolski MJ, Balasubramani GK, et al.

Brachytherapy 2017; (16(2)):330-341 doi:10.1016/j.brachy.2016.12.015.

Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).

Salonia A, Adaikan G, Buvat J, et al.

The journal of sexual medicine 2017; (14(3)):297-315 doi:10.1016/j.jsxm.2016.11.324.

Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.

Chin J, Rumble RB, Kollmeier M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(15)):1737-1743 doi:10.1200/JCO.2016.72.0466.

Histopathology of Prostate Cancer.

Humphrey PA

Cold Spring Harbor perspectives in medicine 2017; (7(10)) doi:10.1101/cshperspect.a030411.

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.

Tzortzis V, Samarinas M, Zachos I, et al.

Hormones (Athens, Greece) 2017; (16(2)):115-123 doi:10.14310/horm.2002.1727.

Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.

Cooney KA

Transactions of the American Clinical and Climatological Association 2017; (128()):14-23.

[Radiation therapy of locally advanced prostate cancer].

Schmidt-Hegemann NS, Li M, Eze C, et al.

Der Urologe. Ausg. A 2017; (56(11)):1402-1409 doi:10.1007/s00120-017-0511-4.

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.

Grubmüller B, Baltzer P, D'Andrea D, et al.

European journal of nuclear medicine and molecular imaging 2018; (45(2)):235-242 doi:10.1007/s00259-017-3858-2.

ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer.

Salembier C, Villeirs G, De Bari B, et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2018; (127(1)):49-61 doi:10.1016/j.radonc.2018.01.014.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, et al.

The Lancet. Oncology 2018; (19(6)):825-833 doi:10.1016/S1470-2045(18)30198-0.

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

, Grossman DC, Curry SJ, et al.

JAMA 2018; (319(18)):1901-1913 doi:10.1001/jama.2018.3710.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Fenton JJ, Weyrich MS, Durbin S, et al.

JAMA 2018; (319(18)):1914-1931 doi:10.1001/jama.2018.3712.

Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.

Dean LW, Assel M, Sjoberg DD, et al.

The Journal of urology 2019; (201(1)):77-82 doi:10.1016/j.juro.2018.07.062.

Comparative study between 68 Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer.

Wong HS, Leung J, Bartholomeusz D, et al.

Journal of medical imaging and radiation oncology 2018; (62(6)):816-822 doi:10.1111/1754-9485.12791.

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.

Body JJ, von Moos R, Niepel D, Tombal B

BMC urology 2018; (18(1)):81 doi:10.1186/s12894-018-0393-9.

Urinary Retention in Adults: Evaluation and Initial Management.

Serlin DC, Heidelbaugh JJ, Stoffel JT

American family physician 2018; (98(8)):496-503.

Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials.

Kee DLC, Gal J, Falk AT, et al.

Cancer treatment reviews 2018; (70()):265-271 doi:10.1016/j.ctrv.2018.10.004.

Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review.

Lawton AJ, Lee KA, Cheville AL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(1)):61-71 doi:10.1200/JCO.2018.78.1211.

Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Egevad L, Judge M, Delahunt B, et al.

Pathology 2019; (51(1)):11-20 doi:10.1016/j.pathol.2018.10.003.

The Quality of Life among Men Receiving Active Surveillance for Prostate Cancer: An Integrative Review.

Dickey SL, Grayson CJ

Healthcare (Basel, Switzerland) 2019; (7(1)) doi:10.3390/healthcare7010014.

Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.

Perera M, Papa N, Roberts M, et al.

European urology 2020; (77(4)):403-417 doi:10.1016/j.eururo.2019.01.049.

Essential Updates in Grading, Morphotyping, Reporting, and Staging of Prostate Carcinoma for General Surgical Pathologists.

Paner GP, Gandhi J, Choy B, Amin MB

Archives of pathology & laboratory medicine 2019; (143(5)):550-564 doi:10.5858/arpa.2018-0334-RA.

Features and Prognostic Significance of Intraductal Carcinoma of the Prostate.

Montironi R, Zhou M, Magi-Galluzzi C, Epstein JI

European urology oncology 2018; (1(1)):21-28 doi:10.1016/j.euo.2018.03.013.

Nomograms Predict Survival Advantages of Gleason Score 3+4 Over 4+3 for Prostate Cancer: A SEER-Based Study.

Zhu X, Gou X, Zhou M

Frontiers in oncology 2019; (9()):646 doi:10.3389/fonc.2019.00646.

PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.

Ahlberg MS, Adami HO, Beckmann K, et al.

BMJ open 2019; (9(8)):e027860 doi:10.1136/bmjopen-2018-027860.

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

Nyberg T, Frost D, Barrowdale D, et al.

European urology 2020; (77(1)):24-35 doi:10.1016/j.eururo.2019.08.025.

ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer.

Ghadjar P, Fiorino C, Munck Af Rosenschöld P, et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2019; (141()):5-13 doi:10.1016/j.radonc.2019.08.027.

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.

Sathianathen NJ, Koschel S, Thangasamy IA, et al.

European urology 2020; (77(3)):365-372 doi:10.1016/j.eururo.2019.09.004.

Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.

Greenberger BA, Zaorsky NG, Den RB

European urology focus 2020; (6(2)):404-418 doi:10.1016/j.euf.2019.11.007.

Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk.

Melloni C, Nelson A

Journal of cardiovascular translational research 2020; (13(3)):451-462 doi:10.1007/s12265-019-09942-w.

A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer.

Holmes A, Kelly BD, Perera M, et al.

World journal of urology 2021; (39(2)):297-306 doi:10.1007/s00345-020-03265-1.

[Malignant Spinal Cord Compression].

Aoyama Y, Kondoh C, Anno M, et al.

Gan to kagaku ryoho. Cancer & chemotherapy 2020; (47(6)):875-880.

The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.

Epstein JI, Amin MB, Fine SW, et al.

Archives of pathology & laboratory medicine 2021; (145(4)):461-493 doi:10.5858/arpa.2020-0015-RA.

Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings.

Lantz A, Falagario UG, Ratnani P, et al.

European urology oncology 2022; (5(2)):187-194 doi:10.1016/j.euo.2020.08.001.

Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy.

Rowe M, Adamson E, McGrane J

International cancer conference journal 2020; (9(4)):217-220 doi:10.1007/s13691-020-00428-0.

Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence.

Seniaray N, Verma R, Khanna S, et al.

Indian journal of urology : IJU : journal of the Urological Society of India 2020; (36(3)):191-199 doi:10.4103/iju.IJU_275_19.

Psychosocial consequences of potential overdiagnosis in prostate cancer a qualitative interview study.

Nielsen SB, Spalletta O, Toft Kristensen MA, Brodersen J

Scandinavian journal of primary health care 2020; (38(4)):439-446 doi:10.1080/02813432.2020.1843826.

Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.

Jakob T, Tesfamariam YM, Macherey S, et al.

The Cochrane database of systematic reviews 2020; (12()):CD013020 doi:10.1002/14651858.CD013020.pub2.

Prostate cancer.

Rebello RJ, Oing C, Knudsen KE, et al.

Nature reviews. Disease primers 2021; (7(1)):9 doi:10.1038/s41572-020-00243-0.

Androgen Receptor Signaling and the Emergence of Lethal Neuroendocrine Prostate Cancer With the Treatment-Induced Suppression of the Androgen Receptor: A Literature Review.

Dhavale M, Abdelaal MK, Alam ABMN, et al.

Cureus 2021; (13(2)):e13402 doi:10.7759/cureus.13402.

A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.

Van den Broeck T, Oprea-Lager D, Moris L, et al.

European urology 2021; (80(5)):531-545 doi:10.1016/j.eururo.2021.04.028.

Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.

Zhu S, Chen J, Ni Y, et al.

The Prostate 2021; (81(11)):721-727 doi:10.1002/pros.24167.

An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.

Gray WK, Day J, Briggs TWR, Harrison S

BJU international 2022; (129(1)):93-103 doi:10.1111/bju.15516.

Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study.

Godtman RA, Persson E, Cazzaniga W, et al.

PloS one 2021; (16(6)):e0253081 doi:10.1371/journal.pone.0253081.

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Sartor O, de Bono J, Chi KN, et al.

The New England journal of medicine 2021; (385(12)):1091-1103 doi:10.1056/NEJMoa2107322.

The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.

Wang NN, Zhou SR, Chen L, et al.

Urologic oncology 2021; (39(12)):831.e19-831.e27 doi:10.1016/j.urolonc.2021.06.004.

PTEN expression and morphological patterns in prostatic adenocarcinoma.

Spieker AJ, Gordetsky JB, Maris AS, et al.

Histopathology 2021; (79(6)):1061-1071 doi:10.1111/his.14531.

Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement.

King MT, Keyes M, Frank SJ, et al.

Brachytherapy 2021; (20(6)):1114-1129 doi:10.1016/j.brachy.2021.07.006.

Supervised pelvic floor muscle exercise is more effective than unsupervised pelvic floor muscle exercise at improving urinary incontinence in prostate cancer patients following radical prostatectomy - a systematic review and meta-analysis.

Baumann FT, Reimer N, Gockeln T, et al.

Disability and rehabilitation 2022; (44(19)):5374-5385 doi:10.1080/09638288.2021.1937717.

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.

Bancroft EK, Page EC, Brook MN, et al.

The Lancet. Oncology 2021; (22(11)):1618-1631 doi:10.1016/S1470-2045(21)00522-2.

Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.

Kaufmann B, Saba K, Schmidli TS, et al.

The Prostate 2022; (82(3)):388-396 doi:10.1002/pros.24286.

Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial.

Delahunt B, Steigler A, Atkinson C, et al.

Pathology 2022; (54(1)):49-54 doi:10.1016/j.pathol.2021.11.004.

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.

Kishan AU, Steigler A, Denham JW, et al.

JAMA oncology 2022; (8(3)):e216871 doi:10.1001/jamaoncol.2021.6871.

Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer.

Tamihardja J, Lawrenz I, Lutyj P, et al.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2022; (198(8)):735-743 doi:10.1007/s00066-022-01953-y.

A Vanguard Approach to the Design and Delivery of Nurse-Led Survivorship Care.

Sara SAM, Chambers SK, Briggs R, et al.

Seminars in oncology nursing 2023; (39(1)):151366 doi:10.1016/j.soncn.2022.151366.

Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.

Agrawal R, Dey A, Datta S, et al.

Cancers 2022; (14(22)) doi:10.3390/cancers14225503.

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.

Fiorica F, Buttigliero C, Grigolato D, et al.

Current oncology (Toronto, Ont.) 2022; (29(12)):9511-9524 doi:10.3390/curroncol29120747.

Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool.

Sahu KK, Johnson ED, Butler K, et al.

Geriatrics (Basel, Switzerland) 2022; (7(6)) doi:10.3390/geriatrics7060133.

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review.

Hatano K, Nonomura N

The world journal of men's health 2023; (41(4)):769-784 doi:10.5534/wjmh.220200.

Prediction of Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging Lesions: A High-volume International Multicenter Study.

Sigle A, Borkowetz A, von Hardenberg J, et al.

European urology focus 2023; (9(4)):606-613 doi:10.1016/j.euf.2023.01.020.

Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort.

Shee K, Cowan JE, Balakrishnan A, et al.

European urology 2023; (84(1)):9-12 doi:10.1016/j.eururo.2023.02.013.

Prostate Cancer Morphologies: Cribriform Pattern and Intraductal Carcinoma Relations to Adverse Pathological and Clinical Outcomes-Systematic Review and Meta-Analysis.

Osiecki R, Kozikowski M, Sarecka-Hujar B, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051372.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Gillessen S, Bossi A, Davis ID, et al.

European journal of cancer (Oxford, England : 1990) 2023; (185()):178-215 doi:10.1016/j.ejca.2023.02.018.

Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.

Chow KM, So WZ, Lee HJ, et al.

European urology 2023; (84(1)):36-48 doi:10.1016/j.eururo.2023.03.001.

Biopsy prostate cancer perineural invasion and tumour load are associated with positive posterolateral margins at radical prostatectomy: implications for planning of nerve-sparing surgery.

van der Slot MA, Remmers S, Kweldam CF, et al.

Histopathology 2023; (83(3)):348-356 doi:10.1111/his.14934.

Simultaneous implant of inflatable penile prosthesis and artificial urinary sphincter: a single high-volume center experience.

Van Huele A, Van Renterghem K

International journal of impotence research 2025; (37(1)):78-81 doi:10.1038/s41443-023-00718-0.

Are magnetic resonance imaging and targeted biopsies needed in men with serum prostate-specific antigen over 10 ng/ml and an abnormal digital rectal examination?

Morote J, Picola N, Paesano N, et al.

Urologic oncology 2023; (41(7)):299-301 doi:10.1016/j.urolonc.2023.05.003.

Spinal Instability as a Prognostic Factor in Patients With Spinal Metastasis of Castration-resistant Prostate Cancer.

Miyaji Y, Nakanishi K, Yamamoto A, et al.

Cancer diagnosis & prognosis 2023; (3(4)):449-456 doi:10.21873/cdp.10238.

Predictors of Long-Term Urinary Incontinence After Robot-Assisted Laparoscopic Prostatectomy.

Yamashita K, Kijima Y, Sekido E, et al.

Research and reports in urology 2023; (15()):387-393 doi:10.2147/RRU.S419903.

Benefits and harms of prostate specific antigen testing according to Australian guidelines.

Caruana M, Gulati R, Etzioni R, et al.

International journal of cancer 2024; (154(4)):648-658 doi:10.1002/ijc.34731.

Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.

Pellegrino F, Stabile A, Sorce G, et al.

European urology focus 2024; (10(4)):634-640 doi:10.1016/j.euf.2023.10.006.

Management of Patients With a Negative Multiparametric Prostate MRI Examination: AJR Expert Panel Narrative Review.

Tan N, Pollock JR, Margolis DJA, et al.

AJR. American journal of roentgenology 2024; (223(2)):e2329969 doi:10.2214/AJR.23.29969.

Narrative review-diagnosing and managing malignant epidural spinal cord compression: an evidence-based approach.

Akanda ZZ, McKay MJ

Annals of translational medicine 2023; (11(11)):386 doi:10.21037/atm-22-3076.

Positive Surgical Margins After Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration.

Bravi CA, Dell'Oglio P, Piazza P, et al.

European urology oncology 2024; (7(4)):821-828 doi:10.1016/j.euo.2023.11.006.

Radiation Therapy Summary of the AUA/ASTRO Guideline on Clinically Localized Prostate Cancer.

Deville C, Kamran SC, Morgan SC, et al.

Practical radiation oncology 2024; (14(1)):47-56 doi:10.1016/j.prro.2023.09.007.

Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.

Bennett R, Li EV, Ho AY, et al.

The Prostate 2024; (84(8)):717-722 doi:10.1002/pros.24687.

First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.

McKay RR, Morgans AK, Shore ND, et al.

Cancer treatment reviews 2024; (126()):102726 doi:10.1016/j.ctrv.2024.102726.

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

Cornford P, van den Bergh RCN, Briers E, et al.

European urology 2024; (86(2)):148-163 doi:10.1016/j.eururo.2024.03.027.

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.

Hussain M, Fizazi K, Shore ND, et al.

JAMA oncology 2024; (10(6)):807-820 doi:10.1001/jamaoncol.2024.0591.

The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy.

Soeterik TFW, Heetman JG, Hermsen R, et al.

European urology oncology 2025; (8(3)):731-738 doi:10.1016/j.euo.2024.11.002.

[Treatment algorithm following first-line therapy failure in metastatic prostate cancer].

Thomas C, Merseburger AS

Urologie (Heidelberg, Germany) 2025; (64(3)):229-236 doi:10.1007/s00120-024-02505-1.

Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

Karimzadeh A, Lehnert W, Koehler D, et al.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2025; (197(9)):1033-1042 doi:10.1055/a-2514-4523.

Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.

Azad AA, Kostos L, Agarwal N, et al.

European urology 2025; (87(4)):455-467 doi:10.1016/j.eururo.2025.01.010.

Genomic prostate score and treatment selection in favourable intermediate-risk prostate cancer.

Margolis E, Lowentritt BH, Pieczonka CM, et al.

BJUI compass 2025; (6(3)):e494 doi:10.1002/bco2.494.

[Active surveillance of prostate cancer].

Bolenz C, Grimm MO, Heidenreich A, et al.

Urologie (Heidelberg, Germany) 2025; (64(6)):595-605 doi:10.1007/s00120-025-02555-z.

British Association of Urological Surgeons (BAUS) consensus document on post-prostatectomy incontinence-stress urinary incontinence.

Bhatt NR, Biers S, Sahai A, et al.

BJU international 2025; (135(6)):887-901 doi:10.1111/bju.16726.

Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review.

Naqvi SAA, Anjum MU, Bibi A, et al.

medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.04.15.25325837.

High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement.

Patel SA, Kollmeier M, Crook J, et al.

Brachytherapy 2025; (24(5)):644-662 doi:10.1016/j.brachy.2025.06.005.

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, et al.

Oncology reviews 2025; (19()):1599292 doi:10.3389/or.2025.1599292.

Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.

Woo S, Tong A, Becker AS, et al.

European radiology 2026; (36(6)):5068-5081 doi:10.1007/s00330-025-12301-w.

Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.

Gao S, Patten ND, Cai C

Journal of the National Cancer Center 2026; (6(1)):58-72 doi:10.1016/j.jncc.2025.05.003.

Imaging of spinal metastases: modality performance, complications, and differential diagnosis.

Beaufort Q, Lefevre V, Carsuzaa T

Neuro-Chirurgie 2026; (72(3)):101804 doi:10.1016/j.neuchi.2026.101804.

True Papillae and Squamous Features in Prostate Carcinoma Represent a Potential Diagnostic Pitfall: Report of 3 Patients.

Grypari IM, Pomoni A, Ganetsou D, et al.

International journal of surgical pathology 2026; (34(6)):1610-1615 doi:10.1177/10668969261436403.

Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.

Sharifi SHH, Williams A, Ryan JT, et al.

BJU international 2026; (138(2)):276-284 doi:10.1111/bju.70303.

Evidence-based management of metastatic spinal cord compression (MSCC): expert recommendations for standardizing care in Spain.

Conde-Moreno AJ, Pérez-Lara A, Ferrer-Abiach C, et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026; doi:10.1007/s12094-026-04345-1.